Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTICLATE vs IPLEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), thereby increasing intestinal absorption and decreasing clearance of substrates; also inhibits CYP3A4 isoenzymes, reducing metabolism of CYP3A4 substrates.
IPLEX (mecasermin rinfabate) is a complex of recombinant human insulin-like growth factor-1 (IGF-1) and its binding protein (IGFBP-3). It activates the IGF-1 receptor, promoting linear growth by stimulating chondrocyte proliferation in epiphyseal growth plates, as well as exerting anabolic effects on muscle and other tissues.
Adjuvant therapy to antibiotics for treatment of refractory infections caused by multidrug-resistant organisms,Off-label: Treatment of hyperuricemia in gout (as a urate-lowering agent when combined with allopurinol),Investigationally: Reversal of P-gp-mediated resistance in certain malignancies
FDA: Treatment of growth failure in children with severe primary IGF-1 deficiency (e.g., Laron syndrome, GH gene deletion, GH receptor defects) or with neutralizing antibodies to GH.,Off-label: Treatment of insulin-like growth factor-1 deficiency in adults; investigational in ALS and other neurodegenerative disorders.
100 mg orally twice daily (12 hours apart) on an empty stomach (1 hour before or 2 hours after meals). Avoid milk, antacids, iron, calcium, magnesium, and zinc within 2 hours of administration.
0.5-2 mg/kg subcutaneously once daily, titrated based on IGF-I levels.
Terminal elimination half-life is approximately 18-22 hours in patients with normal renal function; prolonged to 30-50 hours in moderate renal impairment (Cr Cl 30-50 m L/min).
Terminal elimination half-life of 10-12 hours after subcutaneous administration, supporting twice-daily dosing.
Primarily hepatic via CYP3A4 and CYP2D6; also undergoes glucuronidation and renal excretion.
Mecasermin (IGF-1) is metabolized by proteolytic degradation into amino acids; IGFBP-3 is also proteolytically degraded. No significant cytochrome P450 metabolism.
Renal excretion of unchanged drug accounts for approximately 60% of the dose; fecal elimination via biliary secretion contributes about 30%; minor metabolism (<10%) produces inactive metabolites.
Renal excretion of intact IGF-I and its metabolites; approximately 70% eliminated via kidneys, with 30% biliary/fecal.
Approximately 75-80% bound primarily to serum albumin and to a lesser extent to alpha-1-acid glycoprotein.
Approximately 90% bound to IGF-binding proteins (IGFBPs), primarily IGFBP-3, and a minor fraction to albumin.
Volume of distribution is 1.5-2.5 L/kg, indicating extensive tissue distribution; penetrates well into lung, skin, and soft tissues.
Vd approximately 0.25-0.30 L/kg, indicating distribution primarily to extracellular fluid and well-perfused tissues.
Oral bioavailability is approximately 95% with minimal first-pass metabolism; food reduces absorption by 20-30%.
Subcutaneous: Approximately 80-100%.
e GFR 30-60 m L/min/1.73m²: No adjustment needed; e GFR <30 m L/min: Avoid use (contraindicated due to tetracycline accumulation).
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30–50 m L/min), reduce dose by 25%; monitor IGF-I closely.
Child-Pugh Class A or B: No adjustment; Child-Pugh Class C: Avoid use (insufficient data, potential hepatotoxicity).
Not studied in hepatic impairment; use with caution in Child-Pugh B or C; consider dose reduction based on clinical response and IGF-I monitoring.
Weight ≥45 kg and age ≥12 years: 100 mg every 12 hours for 10 days. Weight <45 kg or age <12 years: Not recommended (risk of permanent tooth discoloration and bone growth inhibition).
0.5-2 mg/kg subcutaneously once daily, titrated to achieve age-appropriate IGF-I levels.
Use with caution due to increased risk of intracranial hypertension and photosensitivity. Consider renal function; no specific dose adjustment beyond renal dosing.
No specific dose adjustment; initiate at lower end of dosing range (0.5 mg/kg/day) due to potential for decreased renal function and increased sensitivity.
None.
Not available (no FDA boxed warning as of current labeling).
May cause significant drug interactions due to inhibition of P-gp, BCRP, and CYP3A4; monitor for increased toxicity of coadministered drugs (e.g., digoxin, methotrexate, anticancer agents). Use with caution in patients with hepatic impairment.
Hypoglycemia (especially in fasted state), intracranial hypertension, slipped capital femoral epiphysis, lymphatic tissue hypertrophy (e.g., tonsillar/adenoid enlargement), allergic reactions, and progression of pre-existing malignancies. Injection site reactions, lipohypertrophy. Risk of hyperglycemia if used in patients with diabetes. Monitor blood glucose, fundoscopy for papilledema, and for signs of hip/knee pain.
Hypersensitivity to active ingredient; concurrent use with narrow therapeutic index drugs that are P-gp or CYP3A4 substrates (e.g., digoxin, colchicine, cyclosporine) unless benefit outweighs risk.
Hypersensitivity to mecasermin rinfabate or any component; active or suspected neoplasia; epiphyseal closure (skeletal maturity); children with closed epiphyses (except if indicated for severe IGF-1 deficiency with open epiphyses).
Dairy products (milk, yogurt, cheese), calcium-fortified foods, and high-calcium meals reduce doxycycline absorption. Take doxycycline at least 1-2 hours before or after consuming these foods. Avoid concurrent use with antacids, iron supplements, bismuth subsalicylate, and magnesium-containing laxatives. Alcohol is not known to interact but may increase gastrointestinal irritation.
No specific food interactions reported. However, to minimize hypoglycemia risk, IPLEX should be administered immediately after a meal or snack. Avoid prolonged fasting. Alcohol use may increase hypoglycemia risk; avoid or limit alcohol consumption.
FDA Pregnancy Category D. Tetracyclines, including doxycycline (active ingredient in ACTICLATE), can cause fetal harm when administered to a pregnant woman. Use during tooth development (second and third trimesters) may cause permanent discoloration of teeth (yellow-gray-brown) and enamel hypoplasia. Use during skeletal development may cause reversible inhibition of bone growth. Avoid during pregnancy; alternative therapy should be considered.
IPLEX (mecasermin rinfabate) is a recombinant human insulin-like growth factor-1 (IGF-1) complexed with IGF-binding protein-3. There are no adequate and well-controlled studies in pregnant women. In animal studies, administration of IGF-1 during organogenesis resulted in fetal growth retardation and increased skeletal abnormalities at doses similar to human exposure. Due to its growth-promoting effects, potential for teratogenicity, and interference with normal fetal development, IPLEX is contraindicated during pregnancy. First trimester: Risk of skeletal and growth abnormalities. Second and third trimesters: continued risk of abnormal fetal growth and development, including organ overgrowth or underdevelopment. Use only if maternal benefits outweigh potential fetal risks; however, generally avoided.
Doxycycline is excreted in human milk at low concentrations. The milk-to-plasma ratio is approximately 0.6-0.9. Theoretical risk of dental discoloration and bone growth inhibition in nursing infants exists due to cumulative effects, although absorption by the infant is limited. Caution is advised; consider temporary discontinuation of breastfeeding during treatment or use alternative agent.
It is unknown whether mecasermin rinfabate or its components (IGF-1, IGFBP-3) are excreted in human milk. Due to the potential for serious adverse reactions in the nursing infant, including growth stimulation and hypoglycemia, breast-feeding is not recommended during IPLEX therapy. No M/P ratio is available.
Doxycycline is contraindicated in pregnancy; no dose adjustment is applicable. If inadvertent exposure occurs in first trimester, no dose adjustment needed, but drug should be discontinued. No pharmacokinetic data suggesting need for dose adjustment if used for life-threatening conditions (e.g., anthrax), but risk-benefit must be carefully assessed.
No specific pharmacokinetic studies of IPLEX in pregnancy are available. The physiological changes of pregnancy (increased plasma volume, altered renal function, increased hepatic metabolism) may affect clearance of mecasermin rinfabate; however, due to its contraindication, dose adjustments during pregnancy are not recommended. If absolutely necessary, use the lowest effective dose and monitor for efficacy and adverse effects. No established dose adjustment guidelines exist.
ACTICLATE (doxycycline hyclate) is a tetracycline antibiotic. Avoid concomitant use with antacids, dairy products, or iron supplements as they chelate doxycycline, reducing absorption. Administer with a full glass of water and avoid lying down for 30 minutes to reduce esophageal irritation. Photosensitivity is common; advise sun avoidance and sunscreen use. Do not use in children <8 years or during pregnancy/lactation due to tooth discoloration and bone growth inhibition. Monitor for pseudomembranous colitis and superinfection.
IPLEX (mecasermin rinfabate) is a complex of recombinant human insulin-like growth factor-1 (rh IGF-1) and its binding protein (rh IGFBP-3). It is indicated for growth failure in children with severe primary IGF-1 deficiency (e.g., Laron syndrome) or with GH gene deletion who have developed neutralizing antibodies to GH. Administer subcutaneously; dose is based on IGF-1 levels. Monitor for hypoglycemia, especially after injection; patients should eat shortly after dosing. Do not use in patients with closed epiphyses or active neoplasia. May cause lymphoproliferative disorders; monitor for splenomegaly, lymphadenopathy.
Take doxycycline exactly as prescribed. Do not skip doses or stop early even if you feel better.,Take with a full glass of water. Avoid lying down for at least 30 minutes after taking to prevent esophageal irritation.,Avoid taking with milk, yogurt, cheese, or calcium-fortified foods. Also avoid antacids, iron, and bismuth subsalicylate within 2 hours of doxycycline.,Use sunscreen and protective clothing; doxycycline increases sensitivity to sunlight and can cause severe sunburn.,If you miss a dose, take it as soon as you remember unless it is near the time of the next dose. Do not double the dose.,Report persistent diarrhea, severe headache, vision changes, or allergic reactions (rash, swelling) to your healthcare provider immediately.
Inject IPLEX within 20 minutes after a meal or snack to prevent hypoglycemia.,Rotate injection sites (abdomen, thigh, upper arm) to avoid lipohypertrophy.,Report symptoms of hypoglycemia (shakiness, sweating, confusion) or increased growth velocity.,Keep a log of blood glucose levels if advised by your doctor.,Store IPLEX in the refrigerator (2-8°C); do not freeze. Protect from light.,Do not share needles or pens; dispose of used needles in a sharps container.,Continue regular follow-up appointments for growth monitoring and blood tests.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTICLATE vs IPLEX, answered by our medical review team.
ACTICLATE is a Tetracycline Antibiotic that works by Inhibits P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), thereby increasing intestinal absorption and decreasing clearance of substrates; also inhibits CYP3A4 isoenzymes, reducing metabolism of CYP3A4 substrates.. IPLEX is a Growth Factor that works by IPLEX (mecasermin rinfabate) is a complex of recombinant human insulin-like growth factor-1 (IGF-1) and its binding protein (IGFBP-3). It activates the IGF-1 receptor, promoting linear growth by stimulating chondrocyte proliferation in epiphyseal growth plates, as well as exerting anabolic effects on muscle and other tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTICLATE and IPLEX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTICLATE is: 100 mg orally twice daily (12 hours apart) on an empty stomach (1 hour before or 2 hours after meals). Avoid milk, antacids, iron, calcium, magnesium, and zinc within 2 hours of administration.. The standard adult dose of IPLEX is: 0.5-2 mg/kg subcutaneously once daily, titrated based on IGF-I levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTICLATE and IPLEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTICLATE is classified as Category C. FDA Pregnancy Category D. Tetracyclines, including doxycycline (active ingredient in ACTICLATE), can cause fetal harm when administered to a pregnant woman. Use during tooth develo. IPLEX is classified as Category C. IPLEX (mecasermin rinfabate) is a recombinant human insulin-like growth factor-1 (IGF-1) complexed with IGF-binding protein-3. There are no adequate and well-controlled studies in . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.